EFG International AG Acquires New Shares in BioMarin Pharmaceutical Inc. $BMRN

EFG International AG bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the 2nd quarter, Holdings Channel reports. The fund bought 18,400 shares of the biotechnology company’s stock, valued at approximately $1,054,000.

Several other hedge funds have also recently added to or reduced their stakes in BMRN. Activest Wealth Management acquired a new position in shares of BioMarin Pharmaceutical during the 4th quarter worth about $26,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at approximately $39,000. CIBC Private Wealth Group LLC raised its position in shares of BioMarin Pharmaceutical by 38.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 179 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in BioMarin Pharmaceutical during the 3rd quarter worth approximately $40,000. Finally, Parallel Advisors LLC boosted its stake in BioMarin Pharmaceutical by 62.2% during the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 295 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on BMRN shares. Oppenheimer upped their target price on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a research note on Friday, August 7th. Weiss Ratings cut shares of BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d)” rating in a research report on Tuesday, August 11th. The Goldman Sachs Group initiated coverage on shares of BioMarin Pharmaceutical in a research report on Monday, May 11th. They set a “neutral” rating and a $69.00 price target on the stock. Sanford C. Bernstein decreased their price target on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Finally, BMO Capital Markets initiated coverage on shares of BioMarin Pharmaceutical in a research report on Wednesday, August 19th. They issued an “outperform” rating and a $98.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $88.79.

BioMarin Pharmaceutical Price Performance

BMRN stock opened at $65.61 on Thursday. The stock has a 50-day moving average price of $61.29 and a two-hundred day moving average price of $58.05. The stock has a market cap of $12.70 billion, a PE ratio of 177.32, a price-to-earnings-growth ratio of 0.47 and a beta of 0.24. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. BioMarin Pharmaceutical Inc. has a 1 year low of $49.26 and a 1 year high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.25. The firm had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The company’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same quarter last year, the business posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities analysts forecast that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current fiscal year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.